AI Article Synopsis
- The study assessed risk factors and management for incidental prostate cancer (iPCa) and clinically significant prostate cancer (icsPCa) in men undergoing Holmium enucleation of the prostate (HoLEP).
- Detection rates for iPCa and icsPCa were found to be 12.8% and 4.4%, with advanced preoperative testing linked to younger age and various prostate health metrics.
- Most iPCa cases were low volume Grade Group 1, suitable for active surveillance, while certain biomarkers like PHI and free PSA levels influenced preoperative decisions regarding biopsies.
Article Abstract
Background: To evaluate contemporary preoperative risk factors and subsequent postoperative management of incidental prostate cancer (iPCa) and incidental clinically significant prostate cancer (icsPCa, Grade Group [GG] ≥ 2 PCa).
Methods: A retrospective cohort of 811 men undergoing Holmium enucleation of the prostate (HoLEP) (January 2021-July 2022) were identified. Advanced preoperative testing was defined as prostate health index (PHI), prostate MRI, and/or negative preoperative biopsy. Descriptive statistics (Whitney-Mann U test, Chi-squared test) and multivariable logistic regression were performed.
Results: iPCa and icsPCa detection rates were 12.8% (104/811) and 4.4% (36/811), respectively. Advanced preoperative testing (406/811, 50%) was associated with younger age and higher (prostate specific antigen) PSA, prostate volume, and PSA density. On multivariable analysis, PHI ≥ 55 was associated with iPCa (OR 6.91, 95% CI 1.85-26.3, p = 0.004), and % free PSA (%fPSA) was associated with icsPCa (OR 0.83, 95% CI 0.67, 0.94, p = 0.01). GG1 disease comprised the majority of iPCa (65%, 68/104) with median 1% involvement. iPCa patients were followed with active surveillance (median follow up 9.3 months), with higher risk patients receiving prostate MRI and confirmatory biopsy. Three patients proceeded to radical prostatectomy or radiation.
Conclusions: In the era of MRI and advanced biomarkers, the majority of iPCa following HoLEP is low volume GG1 suitable for active surveillance. A tentative follow-up strategy is proposed. Patients with PHI ≥ 55 or low %fPSA, even with negative prostate MRI, can consider preoperative prostate biopsy before HoLEP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pros.24781 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vascularized tumor on a microfluidic chip to study mechanisms promoting tumor neovascularization and vascular targeted therapies.
Theranostics
January 2025
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
The cascade of events leading to tumor formation includes induction of a tumor supporting neovasculature, as a primary hallmark of cancer. Developing vasculature is difficult to evaluate but can be captured using microfluidic chip technology and patient derived cells. Herein, we established an approach to investigate the mechanisms promoting tumor vascularization and vascular targeted therapies via co-culture of cancer spheroids and endothelial cells in a three dimensional environment.
View Article and Find Full Text PDF[This corrects the article DOI: 10.3389/fchem.2023.
View Article and Find Full Text PDFAggressive Infection by K1/ST1265 Leading to Multiple Abscesses: Case Report and Literature Review.
Infect Drug Resist
January 2025
Department of Critical Care Medicine, Jiangshan People's Hospital, Quzhou, People's Republic of China.
Hypervirulent (hvKp) has attracted increasing attention in recent years. Diabetes and serotype K1 or K2 are risk factors for invasive liver abscess syndrome including liver abscesses and the metastatic complications such as bacteremia, meningitis, endophthalmitis, and necrotizing fasciitis. Simultaneous infections of the liver, lungs, prostate, brain, and eyes are exceedingly rare.
View Article and Find Full Text PDFAdaptive Treatment of Metastatic Prostate Cancer Using Generative Artificial Intelligence.
Clin Med Insights Oncol
January 2025
Ted Rogers School of Information Technology Management, Toronto Metropolitan University, Toronto, ON, Canada.
Despite the expanding therapeutic options available to cancer patients, therapeutic resistance, disease recurrence, and metastasis persist as hallmark challenges in the treatment of cancer. The rise to prominence of generative artificial intelligence (GenAI) in many realms of human activities is compelling the consideration of its capabilities as a potential lever to advance the development of effective cancer treatments. This article presents a hypothetical case study on the application of generative pre-trained transformers (GPTs) to the treatment of metastatic prostate cancer (mPC).
View Article and Find Full Text PDFComparing surgical techniques: ThuLEP and transurethral BPEP for prostate over 80 grams. Intraoperative and postoperative results. A prospective randomized trial.
Arab J Urol
September 2024
Urology Department, Misr University for Science and Technology, 6th of October City, Egypt.
Background And Purpose: Though TURP remains the primary treatment for BPH, advancements in energy and technology have introduced innovative transurethral surgical options. In this study, we assessed and compared the effectiveness and safety of using thulium laser and bipolar for endoscopic enucleation of prostate exceeding 80 g.
Patients And Methods: Between January 2022 and July 2023, this study enrolled patients with LUTS due to BPH and a prostate size of ≥80 g.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!